Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04633902
Title Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors California Pacific Medical Center Research Institute
Indications

melanoma

Therapies

Olaparib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST